203 related articles for article (PubMed ID: 32905326)
41. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.
Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A
Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845
[TBL] [Abstract][Full Text] [Related]
42. Experimental methods and transport models for drug delivery across the blood-brain barrier.
Fu BM
Curr Pharm Biotechnol; 2012 Jun; 13(7):1346-59. PubMed ID: 22201587
[TBL] [Abstract][Full Text] [Related]
43. T Cell-Mediated Transport of Polymer Nanoparticles across the Blood-Brain Barrier.
Ayer M; Schuster M; Gruber I; Blatti C; Kaba E; Enzmann G; Burri O; Guiet R; Seitz A; Engelhardt B; Klok HA
Adv Healthc Mater; 2021 Jan; 10(2):e2001375. PubMed ID: 33241667
[TBL] [Abstract][Full Text] [Related]
44. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery.
Pardridge WM
Expert Opin Ther Targets; 2015; 19(8):1059-72. PubMed ID: 25936389
[TBL] [Abstract][Full Text] [Related]
45. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation.
Megard I; Garrigues A; Orlowski S; Jorajuria S; Clayette P; Ezan E; Mabondzo A
Brain Res; 2002 Feb; 927(2):153-67. PubMed ID: 11821009
[TBL] [Abstract][Full Text] [Related]
46. Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.
Logan S; Arzua T; Canfield SG; Seminary ER; Sison SL; Ebert AD; Bai X
Compr Physiol; 2019 Mar; 9(2):565-611. PubMed ID: 30873582
[TBL] [Abstract][Full Text] [Related]
47. A filter-free blood-brain barrier model to quantitatively study transendothelial delivery of nanoparticles by fluorescence spectroscopy.
De Jong E; Williams DS; Abdelmohsen LKEA; Van Hest JCM; Zuhorn IS
J Control Release; 2018 Nov; 289():14-22. PubMed ID: 30243824
[TBL] [Abstract][Full Text] [Related]
48. In Vivo and In Vitro Evidence for Brain Uptake of 4-Phenylbutyrate by the Monocarboxylate Transporter 1 (MCT1).
Lee NY; Kang YS
Pharm Res; 2016 Jul; 33(7):1711-22. PubMed ID: 27026010
[TBL] [Abstract][Full Text] [Related]
49. Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies.
Hanes J; Dobakova E; Majerova P
Curr Pharm Des; 2020; 26(13):1448-1465. PubMed ID: 32178609
[TBL] [Abstract][Full Text] [Related]
50. Evolving new-age strategies to transport therapeutics across the blood-brain-barrier.
Choudhari M; Hejmady S; Narayan Saha R; Damle S; Singhvi G; Alexander A; Kesharwani P; Kumar Dubey S
Int J Pharm; 2021 Apr; 599():120351. PubMed ID: 33545286
[TBL] [Abstract][Full Text] [Related]
51. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models.
Lundquist S; Renftel M; Brillault J; Fenart L; Cecchelli R; Dehouck MP
Pharm Res; 2002 Jul; 19(7):976-81. PubMed ID: 12180550
[TBL] [Abstract][Full Text] [Related]
52. 3D Self-Organized Human Blood-Brain Barrier in a Microfluidic Chip.
Campisi M; Lim SH; Chiono V; Kamm RD
Methods Mol Biol; 2021; 2258():205-219. PubMed ID: 33340363
[TBL] [Abstract][Full Text] [Related]
53. Efflux Pump Substrates Shuttled to Cytosolic or Vesicular Compartments Exhibit Different Permeability in a Quantitative Human Blood-Brain Barrier Model.
Ruano-Salguero JS; Lee KH
Mol Pharm; 2018 Nov; 15(11):5081-5088. PubMed ID: 30212633
[TBL] [Abstract][Full Text] [Related]
54. Human iPSC-Derived Blood-Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?
Appelt-Menzel A; Oerter S; Mathew S; Haferkamp U; Hartmann C; Jung M; Neuhaus W; Pless O
Curr Protoc Stem Cell Biol; 2020 Dec; 55(1):e122. PubMed ID: 32956578
[TBL] [Abstract][Full Text] [Related]
55. In vitro modeling of blood-brain barrier and interface functions in neuroimmune communication.
Erickson MA; Wilson ML; Banks WA
Fluids Barriers CNS; 2020 Mar; 17(1):26. PubMed ID: 32228633
[TBL] [Abstract][Full Text] [Related]
56. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
57. Inhibitory effects of alcohol on glucose transport across the blood-brain barrier leads to neurodegeneration: preventive role of acetyl-L: -carnitine.
Abdul Muneer PM; Alikunju S; Szlachetka AM; Haorah J
Psychopharmacology (Berl); 2011 Apr; 214(3):707-18. PubMed ID: 21079922
[TBL] [Abstract][Full Text] [Related]
58. Blood-brain barrier biology and methodology.
Pardridge WM
J Neurovirol; 1999 Dec; 5(6):556-69. PubMed ID: 10602397
[TBL] [Abstract][Full Text] [Related]
59. An Improved in Vitro Blood-Brain Barrier Model for Applications in Therapeutics' Delivery to Brain.
Kuo CF; Majd S
Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():3331-3334. PubMed ID: 33018717
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Blood-Brain Barrier Models for
Song Y; Cai X; Du D; Dutta P; Lin Y
ACS Appl Bio Mater; 2019 Mar; 2(3):1050-1055. PubMed ID: 31984375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
